Following BTK inhibition, CLL cells only select gain-of-function alterations that are mediated by NF-κB signaling, highlighting BTK’s significant role in BCR-induced activation of NF-κB (179). This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.